son of T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (255)	11/11/1999 7:48:00 AM
From: WTDEC	of 673

Rick, FYI. Best regards, Walter Thursday November 11, 6:04 am Eastern Time Company Press Release Scientists Present New Research That Supports Aphton's Anti-Gastrin Therapy For Gastrointestinal Cancers TUCSON, Ariz.--(BW HealthWire)--November 11, 1999--Aphton Corporation (Nasdaq:APHT - news) today announced new results that offer further support to the company's anti-gastrin approach in the treatment of gastric and colon cancers. During the three day Third International Conference on Gastrin, scientists from the UK presented findings from six studies that resulted from collaborative research with Aphton scientists. These presentations as well as other published scientific research continue to provide the foundation for Aphton's anti-gastrin drug as an emerging new therapy for gastrointestinal cancers. Aphton is in late-stage clinical trials treating patients with gastric (stomach), pancreatic and colorectal cancer. <SNIP> biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next